Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1150315 | 0.88 | HTR2C (0.43) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL7245273 | 0.87 | MEN1 (0.49) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL630773 | 0.87 | MEN1 (0.49) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL317040 | 0.82 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL205894 | 0.82 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL630728 | 0.82 | MEN1 (0.47) | MEN1KMT2ANPSR1 | |
| SCHEMBL630719 | 0.81 | MEN1 (0.46) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL630809 | 0.81 | MEN1 (0.48) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL23825226 | 0.80 | HTR2C (0.43) | MEN1KMT2ANPSR1NPC1RAB9A | |
| SCHEMBL1834783 | 0.79 | HTR2C (0.49) | MEN1KMT2ANPSR1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3427738-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2021-12-01 | — | — | EP | disclosed |
| US-10874673-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-12-29 | — | — | US | disclosed |
| US-20190151314-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2019-05-23 | — | — | US | disclosed |
| EP-3427738-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2019-01-16 | — | — | EP | disclosed |
| US-10039762-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2018-08-07 | — | — | US | disclosed |
| EP-3141252-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2018-07-25 | — | — | EP | disclosed |
| US-20180078553-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2018-03-22 | — | — | US | disclosed |
| US-9808459-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170100400-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2017-04-13 | — | — | US | disclosed |
| EP-3141252-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Inc. (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9518056-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-12-13 | — | — | US | disclosed |
| EP-2442809-B1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMA (US) | 2016-08-31 | — | — | EP | disclosed |
| US-20160152614-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2016-06-02 | — | — | US | disclosed |
| US-9345708-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140296201-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED | 2014-10-02 | — | — | US | disclosed |
| US-8829007-B2 | Inhibitors of influenza viruses replication | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-09-09 | — | — | US | disclosed |
| US-20140142119-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-05-22 | — | — | US | disclosed |
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-05 | — | — | US | disclosed |
| EP-2442809-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | Vertex Pharmaceuticals Incorporated (US) | 2012-04-25 | — | — | EP | disclosed |
| WO-2010148197-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180078553-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | MEN1 3469/4885KMT2A 1893/4885NPSR1 2470/4885 |
| US-20190151314-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | MEN1 3469/4885KMT2A 1893/4885NPSR1 2470/4885 |
| US-20140296201-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | MEN1 3469/4885KMT2A 1893/4885NPSR1 2470/4885 |
| US-10874673-B2 | Inhibitors of influenza viruses replication | ACE, IRF3, ACE2 | MEN1 3469/4885KMT2A 1893/4885NPSR1 2470/4885 |
| US-20120171245-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | MEN1 3469/4885KMT2A 1893/4885NPSR1 2470/4885 |
| US-20160152614-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | MEN1 3469/4885KMT2A 1893/4885NPSR1 2470/4885 |
| US-10039762-B2 | Inhibitors of influenza viruses replication | ACE, IRF3, ACE2 | MEN1 3469/4885KMT2A 1893/4885NPSR1 2470/4885 |
| US-20170100400-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | MEN1 3469/4885KMT2A 1893/4885NPSR1 2470/4885 |
| US-20140142119-A1 | INHIBITORS OF INFLUENZA VIRUSES REPLICATION | ACE, IRF3, ACE2 | MEN1 3469/4885KMT2A 1893/4885NPSR1 2470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.